What changed from existing technology?
This study tested a combination of drugs for endometrial cancer. It found that adding a third drug didn't improve outcomes for most patients, but it might help those who had previous hormone therapy.
The study demonstrates that adding ribociclib to everolimus and letrozole does not improve outcomes for most patients with recurrent endometrial cancer, but may benefit those who previously received endocrine therapy.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial. In this phase II trial, patients with endometrial cancer (EC) were
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The combination may be considered for patients with recurrent endometrial cancer who have previously received endocrine therapy, but further research is needed to confirm these findings.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.